CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Overland Pharmaceuticals

Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world. By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas. Through formative partnerships, Overland will drive the development and commercialization of the most promising advances in medicine.

ETHEX

ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BCM GROUP

BCM GROUP is a Hamburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RSP Nutrition

RSP Nutrition is a company that makes premium nutritional supplements that inspire customers to live healthy, active lifestyles and achieve their fitness goals.

THE PLANNING SHOP International

THE PLANNING SHOP International is a Jamison, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.